Impact of NaHCO3- on Exercise Hyperpnea
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03057535|
Recruitment Status : Completed
First Posted : February 20, 2017
Last Update Posted : February 20, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Ventilation||Drug: Sodium Bicarbonate Drug: Sodium Chloride||Early Phase 1|
The ventilatory response (V̇E) to exercise-induced increases in the rate of CO2 production (V̇CO2) depends on the regulated level of arterial PCO2 (PaCO2) and the dead space to tidal volume ratio (VD/VT).
An abnormally high V̇E/V̇CO2 response to exercise, reflecting a high VD/VT and/or low PaCO2 equilibrium point, is a key pathophysiological feature of patients with chronic cardiopulmonary disease, including heart failure, pulmonary arterial hypertension, interstitial lung disease and chronic obstructive pulmonary disease. In these patient groups, exercise ventilatory inefficiency is associated with: disease severity and progression; exercise intolerance; exertional breathlessness; and increased risk of hospitalization, major cardiac events and mortality. It follows that any intervention capable of decreasing the V̇E/V̇CO2 response to exercise has the potential to improve clinical and/or patient-reported outcomes. Unfortunately, our ability to enhance exercise ventilatory efficiency is limited by the fact that, with the possible exception of lung volume reduction surgery in chronic obstructive pulmonary disease and pulmonary vasodilator therapy in pulmonary arterial hypertension and heart failure, ventilation-perfusion abnormalities reflecting a high VD/VT are often irreversible.
A largely unexplored approach to decreasing the V̇E/V̇CO2 response to exercise is increasing the PaCO2 equilibrium point by inducing a metabolic alkalosis via administration of an alkalizing agent such as sodium bicarbonate (NaHCO3). Thus, the primary objective of this randomized, double blind, placebo controlled, crossover study was to test the hypothesis that increasing the PaCO2 equilibrium point via induced acute metabolic alkalosis by single-dose oral administration of NaHCO3 would decrease in the V̇E/V̇CO2 ratio at its lowest point ("nadir") during high-intensity constant-load cycle exercise testing in healthy adults.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Effect of Induced Metabolic Alkalosis by Sodium Bicarbonate Administration on the Ventilatory Response to Exercise in Healthy Adults|
|Actual Study Start Date :||May 2015|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||September 2016|
Experimental: Sodium Bicarbonate
Ingestion of sodium bicarbonate (0.3 g/kg of body mass)
Drug: Sodium Bicarbonate
Placebo Comparator: Sodium Chloride
Ingestion of sodium chloride (4 g)
Drug: Sodium Chloride
- Ventilatory equivalent to carbon dioxide (V̇E/V̇CO2) at its lowest point ("nadir") during exercise [ Time Frame: Participants will be followed until all study visits are complete, an expected average of 3 weeks ]The V̇E/V̇CO2 nadir will be identified as the lowest 30-sec average data point during constant-load cycle exercise testing
- Partial pressure of carbon dioxide in the arterialized capillary blood (PacCO2) [ Time Frame: Time Frame: Participants will be followed until all study visits are complete, an expected average of 3 weeks ]PacCO2 (mmHg) will be measured at rest 90-min post-dose
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03057535
|McGill University, Department of Kinesiology & Physical Education, Clinical Exercise & Respiratory Physiology Laboratory|
|Montreal, Quebec, Canada, H2W 1S4|
|Principal Investigator:||Dennis Jensen, Ph.D.||McGill University|